Predictive markers of radiation pneumonitis

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2421-2432

  Provatopoulou, X ^a   Athanasiou, E ^b   Gounaris, Antonia ^a  

^a Hellenic Anticancer Institute   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Breast cancer; Predictive markers; Radiation pneumonias; Radiation therapy; Review

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19 FRAGMENT; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN; THROMBOMODULIN; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE PHASE RESPONSE; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DOSIMETRY; EARLY DIAGNOSIS; HUMAN; LUNG ALVEOLUS CELL TYPE 2; LUNG CANCER; LUNG FIBROSIS; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; NONHUMAN; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIATION DOSE; RADIATION HAZARD; RADIATION PNEUMONIA; RADIODIAGNOSIS; TISSUE INJURY;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; PREDICTIVE VALUE OF TESTS; RADIATION PNEUMONITIS;

EID: 48849105368     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (127)

1. Fisher B, Dignam J, Wolmark N, Mamounas E, Constantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N and Kavanah M: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16: 441-452, 1998.
2. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sulvester R, Mignolet F, Bartelink H and van Dongen JA: Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 355: 528-533, 2000.
3. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER and Wolmark N: Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 28: 400-418, 2001.
4. Clarke RM, Whelan T, Levine M, Roberts R, Willan A, McCulloch P, Lipa M, Wilkinson RH and Mahoney LJ: Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst 88: 1659-1664, 1996.
5. Holli K, Saaristo R, Isola J, Joensuu H and Hakama M: Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer 84: 164-169, 2001.
6. Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabar L, Nordgren H and Adami HO: 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol 17: 2326-2333, 1999.
7. Arriagada R, Le MG, Rochard F and Contesso G: Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Insitut Gustave-Roussy Breast Cancer Group. J Clin Oncol 14: 1558-1564, 1996.
8. Morris AD, Morris RD, Wilson JF, White J, Steinberg S, Okunieff P, Arriagada R, Le MG, Blichert-Toft M and van Dongen JA: Breast-conserving therapy vs. mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J Sci Am 3: 6-12, 1997.
9. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, van der Schueren E, Helle PA, van Zijl K and Bartelink H: Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organisation for Research and Treatment of Cancer 10801 trial. J Nat Cancer Inst 92: 1143-1150, 2000.
10. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M and Marubini E: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347: 1227-1232, 2002.
11. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH and Wolmark N: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347: 1233-1241, 2002.
12. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C and Wang Y; Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366: 2087-2106, 2005.
13. Whelan TJ, Julian J, Wright J, Jadad AR and Levine ML: Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18: 1220-1229, 2000.
14. Vicini FA, Kestin L and Huang R: Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer 97: 910-919, 2003.
15. Vinh-Hung V and Verschraegen C: Breast-conserving surgery with or without radiotherapy: pooled analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 96: 115-121, 2004.
16. Levitt SH, Aeppli DM and Nierengarten ME: The impact of radiation on early breast carcinoma survival. A Bayesian analysis. Cancer 78: 1035-1042, 1996.
17. Levitt SH, Aeppli DM and Nierengarten ME: The importance of local control in the conservative treatment of breast cancer. Acta Oncol 34: 839-844, 1995.
18. Van de Steene J, Soete G and Storme G: Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. Radiother Oncol 55: 263-272, 2000.
19. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CG, Mouridsen HT, Jensen MB and Zedeler K: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b trial. N Engl J Med 337: 949-955, 1997.
20. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, Kamby C, Kjaer M, Gadeberg CG, Rasmussen BB, Blichert-Toft M and Mouridsen HT: Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353: 1641-1648, 1999.
21. Recht A, Edge SB, Solin LJ, Robinson DS, Estrabrook A, Fine RE, Fleming GF, Formenti S, Hudis C, Kirshner JJ, Krause DA, Kuske RR, Langer AS, Sledge GW Jr, Whelan TJ and Pfister DG: Postmastectomy radiotherapy: Guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1539-1569, 2001.
22. Gebski V, Lagleva M, Keech A, Simes J and Langlands AO: Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective. J Natl Cancer Inst 98: 26-38, 2006.
23. Bellon JR, Katz A and Tangian A: Radiation therapy for breast cancer. Hematol Oncol Clin N America 20: 239-257, 2006.
24. Early Breast Cancer Trialists' Collaborative Group: Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355: 1757-1770, 2000.
25. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR and Vaughn DJ: ASCO Cancer Survivorship Expert Panel: American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25: 3991-4008, 2007.
26. Mehta V: Radiation pneumonitis and pulmonary fibrosis in non-small cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63: 5-24, 2005.
27. Marks LB, Yu X, Vujaskovic Z, Small W, Folz R and Anscher MS: Radiation-induced lung injury. Sem Radiat Oncol 13: 333-345, 2003.
28. Tsoutsou PG and Koukourakis MI: Radiation pneumonitis and fibrosis: Mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 66: 1281-1293, 2006.
29. Ghafoori P, Marks LB, Vujaskovic Z and Kelsey CR: Radiation-induced lung injury. Assessment, management, and prevention. Oncology 22: 37-47, 2008.
30. Park KJ, Chung JY, Chun MS and Suh JH: Radiation-induced lung disease and the impact of radiation methods on imaging features. Radiographics 20: 83-98, 2000.
31. Rubin P, Jonston CJ, Williams JP, McDonald S and Finkelstein JN: A perpetual cascade of cytokines post-irradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33: 99-109, 1995.
32. Kong FM, Haken RT, Eisbruch A and Lawrence TS: Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 32(Suppl 3): S42-S54, 2005.
33. Jung JI, Kim HH, Park SH, Song SW, Chung MH, Kim HS, Kim KJ, Ahn MI, Seo SB and Hahn ST: Thoracic manifestations of breast cancer and its therapy. Radiographics 24: 1369-1285, 2004.
34. Clifford Chao KS, Ferez CA and Brady LW: Radiation Oncology Management Decisions. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins, pp. 333-344, 2002.
35. Bell J, McGivern D, Bullimore J, Hill J, Davies ER and Goddard P: Diagnostic imaging of post-irradiation changes in the chest. Clin Radiol 39: 109-119, 1988.
36. Marks LB, Spencer DP, Bentel CG, Ray SK, Sherouse GW, Sontag MR, Coleman RE, Jaszczak RJ, Turkington TG and Tapson V: The utility of SPECT lung perfusion scans in minimizing and assessing the physiological consequences of thoracic irradiation. Int J Radiat Oncol Biol Phys 26: 659-668, 1993.
37. Senkus-Konefka E and Jassem J: Complications of breast cancer radiotherapy. Clin Oncol 18: 229-235, 2006.
38. Van Dyk J, Keane TJ, Kan S, Rider WD and Fryer CJ: Radiation pneumonitis following large single dose irradiation: A reevaluation based on absolute dose to the lung. Int J Radiat Oncol Biol Phys 7: 461-467, 1981.
39. Rothwell RI, Kelly SA and Joslin CA: Radiation pneumonitis in patients treated for breast cancer. Radiother Oncol 4: 9-14, 1985.
40. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ and Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21: 109-122, 1991.
41. Kwa SL, Lebesque JV, Theuws JC, Marks LB, Munley MT, Bentel G, Oetzel D, Spann U, Graham MV, Drzymala RE, Purdy JA, Lichter AS, Martel MK and Ten Haken RK: Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42: 1-9, 1998.
42. Kahán Z, Csenki M, Varga Z, Szil E, Cserháti A, Balogh A, Gyulai Z, Mándi Y, Boda K and Thurzó L: The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 68: 673-681, 2007.
43. Schallenkamp JM, Miller RC, Brinkmann DH, Foote T and Garces YI: Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat Oncol Biol Phys 67: 410-416, 2007.
44. Van Dyk J, Mah K and Keane TJ: Radiation-induced lung damage: Dose-time-fractionation considerations. Radiother Oncol 14: 55-69, 1989.
45. Bentzen SM, Skoczylas JZ and Bernier J: Quantitative clinical radiobiology of early and late lung reactions. Int J Radiat Biol 76: 453-462, 2000.
46. Movsas B, Raffin TA, Epstein AH and Link CJ: Pulmonary radiation injury. Chest 111: 1061-1076, 1997.
47. Mah K, Keane TJ, Van Dyk J, Braban LE, Poon PY and Hao Y: Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation-induced lung damage: A prospective clinical study. Int J Radiat Oncol Biol Phys 28: 563-574, 1994.
48. Tsujino K, Hirota S, Endo M, Obayashi K, Kotani Y, Satouchi M, Kado T and Takada Y: Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55: 110-115, 2003.
49. Lopez RM and Cerezo PL: Toxicity associated to radiotherapy treatment in lung cancer patients. Clin Trans Oncol 9: 506-512, 2007.
50. Lind PA, Marks LB, Hollis D, Fan M, Zhou SM, Munley MT, Shafman TD, Jaszczak RJ and Coleman RE: Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol phys 54: 340-347, 2002.
51. Johansson S, Bjermer L, Franzen L and Henriksson R: Effects of ongoing smoking on the development of radiation-induced pneumonitis in breast cancer and oesophagus cancer patients. Radiother Oncol 49: 41-47, 1998.
52. Yorke ED, Jackson A, Rosenzweig KE, Merrick SA, Gabrys D, Venkatraman ES, Burman CM, Leibal SA and Ling CC: Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54: 329-339, 2002.
53. Khan MA, Van Dyk J, Yeung IW and Hill RP: Partial volume rat lung irradiation; assessment of early DNA damage in different lung regions and effect of radical scavengers. Radiother Oncol 66: 95-102, 2003.
54. Kasten-Pisula U, Tastan H and Dikomey E: Huge differences in cellular radiosensitivity due to only very small variations in double-strand break repair capacity. Int J Radiat Biol 81: 409-419, 2005.
55. Kong FM, Anscher MS, Sporn TA, Washington MK, Clough R, Barcellos-Hoff MH and Jirtle RL: Loss of heterozygocity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2K) locus predisposes patients to radiation-induced lung injury. Int J Radiat Oncol Biol Phys 49: 35-41, 2001.
56. Madani I, De Ruyck K, Goeminne H, De Neve W, Thierens H and Van Meerbeeck J: Predicting risk of radiation-induced lung injury. J Thorac Oncol 2: 864-874, 2007.
57. Das SK, Zhou S, Zhang J, Yin FF, Dewhirst MW and Marks LB: Predicting lung radiotherapy-induced pneumonitis using a model combining parametric Lyman probit with nonparametric decision trees. Int J Radiat Oncol Biol Phys 68: 1212-1221, 2007.
58. Tsougos I, Nilsson P, Theodorou K, Kjellén E, Ewers SB, Jarlman O, Lind BK, Kappas C and Mavroidis P: NTCP modelling and pulmonary function tests evaluation for the prediction of radiation induced pneumonitis in non-small cell lung cancer radiotherapy. Phys Med Biol 52: 1055-1073, 2007.
59. Semenenco VA and Li XA: Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. Phys Med Biol 53: 737-755, 2008.
60. Chen S, Zhou S, Yin FF, Marks LB and Das SK: Using patient data similarities to predict radiation pneumonitis via a self-organizing map. Phys Med Biol 53: 203-216, 2008.
61. Chen S, Zhou S, Yin FF, Marks LB and Das SK: Investigation of the support vector machine algorithm to predict lung radiation-induced pneumonitis. Med Phys 34: 3808-3814, 2007.
62. Brink C, Berg M and Nielsen M: Sensitivity of NTCP parameter values against a change of dose calculation algorithm. Med Phys 34: 3579-3586, 2007.
63. Chen S, Zhou S, Zhang J, Yin FF, Marks LB and Das SK: A neural network model to predict lung radiation-induced pneumonitis. Med Phys 34: 3420-3427, 2007.
64. Bradley JD, Hope A, El Naga I, Apte A, Lindsay PE, Bosch W, Matthews J, Sause W, Graham MV and Deasy JO: RTOG: A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys 69: 985-992, 2007.
65. Williams J, Chen Y, Rubin P, Finkelstein J and Okunieff P: The biological basis of a comprehensive grading system for the adverse effects of cancer treatment. Semin Rad Oncol 13: 182-188, 2003.
66. Chen Y, Okunieff P and Ahrendt SA: Translational research in lung cancer. Semin Surg Oncol 21: 205-219, 2003.
67. Roberts CM, Foulcher E, Zaunders JJ, Bryant DH, Freund J, Cairns D, Penny R, Morgan GW and Breit SN: Radiation pneumonitis: a possible lymphocyte-mediated hypersensitivity reaction. Ann Intern Med 118: 696-700, 1993.
68. Trott KM, Herrmann T and Kasper M: Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys 58: 463-469, 2004.
69. Coleman CN and Harris JR: Current scientific issues related to clinical radiation oncology. Radiat Res 150: 125-133, 1998.
70. Hallahan D, Kuchibhotla J and Wyble C: Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 56: 5150-5155, 1996.
71. Wu NZ, Ross BA, Gulledge C, Klitzman B, Dodge R and Dewhirst MW: Differences in leukocyte-endothelium interactions between normal and adenocarcinoma bearing tissues in response to radiation. Br J Cancer 69: 883-889, 1994.
72. Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, Finkelstein JN, Rubin P and Okunieff P: Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 12(Suppl 1): 26-33, 2002.
73. Ward WF, Lin PJ, Wong PS, Behnia R and Jalali N: Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high-resolution computed tomography. Radiat Res 135: 81-87, 1993;.
74. Rosiello RA, Merrill WW, Rockwell S, Carter D, Cooper JA Jr, Care S and Amento EP: Radiation pneumonitis: Bronchoalveolar lavage assessment and modulation by a recombinant cytokine. Am Rev Respir Dis 148: 1671-1676, 1993.
75. Gurley LR, London JE, Tietjen GL, van der Kogel AJ, Dethloff LA and Lehnert BE: Lung hyperpermeability and changes in biochemical constituents in bronchoalveolar lavage fluids following X irradiation of the thorax. Radiat Res 134: 151-159, 1993.
76. Lehnert BE, Dethloff LA, Finkelstein JN and van der Kogel AJ: Temporal sequence of early alterations in rat lung following thoracic X-irradiation. Int J Radiat Biol 60: 657-675, 1991.
77. Morgan GW and Breit SN: Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys 31: 361-369, 1995.
78. Rubin P, Filkenstein JN, Siemann DW, Shapiro DL, Van Houtte P and Penney DP: Predictive biochemical assays for late radiation effects. Int J Radiat Oncol Biol Phys 12: 469-476, 1986.
79. Rubin P, McDonald S, Maasilta P, Finkelstein JN, Shapiro DL, Penney D and Gregory PK: Serum markers for the prediction of pulmonary radiation syndromes. Part I: Surfactant apoprotein. Int J Radiat Oncol Biol Phys 17: 553-558, 1989.
80. Frater-Schroder M, Muller G, Birchmeier W and Bohlen P: Transforming growth factor-beta inhibits endothelial cell proliferation. Biochem Biophys Res Commun 137: 295-302, 1986.
81. Border WA and Ruoslahti E: Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 90: 1-7, 1992.
82. Barcellos-Hoff MH: How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat Res 150: S109-S120, 1998.
83. Anscher MA, Kong FM, Andrews K, Clough R, Marks LB, Bentel G and Jirtle RL: Plasma transforming growth factor β1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 41: 1029-1035, 1998.
84. Vujaskovic Z and Groen HJ: TGF-beta, radiation-induced pulmonary injury and lung cancer. Int J Radiat Biol 76: 511-516, 2000.
85. Zhao L, Sheldon K, Chen M, Yin MS, Hayman JA, Kalemkerian GP, Arenberg D, Lyons SE, Curtis JL, Davis M, Cease KB, Anscher MS, Lawrence TS and Kong FM: The predictive role of plasma TGF-betal during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 59: 232-239, 2008.
86. Fu XL, Huang H, Bentel G, Clough R, Jirtle RL, Kong FM, Marks LB and Anscher MS: Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V30 and transforming growth factor β. Int J Radiat Oncol Biol Phys 50: 899-908, 2001.
87. De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS and Lebesque JV: Significance of plasma transforming growth factor-β levels in radiotherapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 58: 1378-1387, 2004.
88. Novakova-Jiresova A, Van Gameren MM, Coppes RP, Kampinga HH and Groen HJ: Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 71: 183-189, 2004.
89. Evans ES, Kocak Z, Zhou SM, Kahn DA, Huang H, Hollis DR, Light KL, Anscher MS and Marks LB: Does transforming growth factor-β1 predict for radiation-induced pneumonitis in patients treated for lung cancer? Cytokine 35: 186-192, 2006.
90. Kovacs EJ: Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today 12: 17-23, 1991.
91. Simeonova PP, Toriumi W, Kommineni G, Erkan M, Munson AE, Rom WN and Luster MI: Molecular regulation of IL-6 activation by asbestos in lung epithelial cells: Role of reactive oxygen species. J Immunol 159: 3921-3928, 1997.
92. Matsushima K, Larsen CG, DuBois GC and Oppenheim JJ: Purification and characterisation of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 169: 1485-1490, 1989.
93. Yoshimura T, Robinson EA, Appella E, Matsushima K, Showalter SD, Skeel A and Leonard EJ: Three forms of monocyte-derived neutrophil chemotactic factor (MDNCF) distinguished by different lengths of the amino-terminal sequence. Mol Immunol 26: 87-93, 1989.
94. Mukaida N: Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 284: L566-L577, 2003.
95. Heidenmann J, Ogawa H, Dwinell MB, Rafiee P, Maaser C, Gockel HR, Otterson MF, Ota DM, Lugering N, Domschke W and Binion DG: Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 278: 8508-8515, 2003.
96. Li A, Dubey S, Varney ML, Dave BJ and Singh RK: IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 3369-3376, 2003.
97. Dunlevy JR and Couchman JR: Interleukin-8 induces motile behaviour and loss of focal adhesions in primary fibroblasts. J Cell Sci 108: 311-321, 1995.
98. Simonet WS, Hughes TM, Nguyen HQ, Trebasky LD, Danilenko DM and Medlock ES: Long-term impaired neutrophil migration in mice overexpressing human interleukin-8. J Clin Invest 94: 1310-1319, 1994.
99. Hart JP, Broadwater G, Rabbani Z, Moeller BJ, Clough R, Huang D, Sempowski GA, Dewhirst M, Pizzo SV, Vujaskovic Z and Anscher MS: Cytokine profiling for prediction of symptomatic radiation-induced lung injury. Int J Radiat Oncol Biol Phys 63: 1448-1454, 2005.
100. Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY, Kuo SH and Luh KT: Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small cell lung cancer. Am J Respir Crit Care Med 162: 1957-1963, 2000.
101. Mocellin S, Panelli M, Wang E, Nagorsen D and Marincola FM: The dual role of IL-10. Trends Immunol 24: 36-42, 2003.
102. Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Barbacane RC, Castellani ML, Felaco M, Boucher W, Letourneau R and Theoharides TC: IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett 86: 123-129, 2003.
103. Chen Y, Ollivier H, Williams J, Okunieff P, Smudzin T and Rubin P: Interleukin (IL)-1A and IL-6: Application to the predictive diagnostic testing of radiation pneumonitis. Int J Oncol Biol Phys 62: 260-266, 2005.
104. Arpin D, Perol D, Blay JY, Falchero L, Claude L, Vuillermoz-Blas S, Martel-Lafay I, Ginestet C, Anberti L, Nosov D, Etienne-Mastroianni B, Comn V, Perol M, Guerin JC, Cordier JF and Carrie C: Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol 23: 8748-8756, 2005.
105. Kaxana A, Shioya S, Katoh H, Tsuji C, Tsuda M and Ohta Y: Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen 1 on alveolar macrophages in the acute stage of radiation-induced lung injury in rats. Radiat Res 147: 431-436, 1997.
106. Hallahan DE and Virudachalam S: Ionizing radiation mediates expression of cell adhesion molecules in distinct histological patterns within the lung. Cancer Res 57: 2096-2099, 1997.
107. Ishii Y and Kitamura S: Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis. Eur Respir J 13: 733-738, 1999.
108. Tsujisaki M, Imai K, Hirata H, Hanzawa Y, Masuya J, Nakano T, Sugiyama T, Matsui M, Hinoda Y and Yachi A: Detection of circulating intercellular adhesion molecule-1 in malignant diseases. Clin Exp Immunol 81: 3-8, 1991.
109. Kuroki Y and Voelker DR: Pulmonary surfactant proteins. J Biol Chem 24: 93-101, 1994.
110. Kremlev SG and Phelps DS: Surfactant protein A stimulation of inflammatory cytokine and immunoglobulin production. Am J Physiol 267: L712-719, 1994.
111. Weissbach S, Neuendank A, Pettersson M, Schaberg T and Pison U: Surfactant protein A modulates release of reactive oxygen species from alveolar macrophages. Am J Physiol 267: L660-666, 1994.
112. Kuan SF, Rust K and Crouch E: Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coli-binding protein in broncoalveolar lavage. J Clin Invest 90: 97-106, 1992.
113. Sasaki R, Soejima T, Matsumoto A, Maruta T, Yamada K, Ota Y, Kawabe T, Nishimura H, Sakai E, Ejima Y and Sugimura K: Clinical significance of serum pulmonary surfactant proteins A and D for the early detection of radiation pneumonitis. Int J Radiat Oncol Biol Phys 50: 301-307, 2001.
114. Takahashi H, Imai Y, Fujishima T, Shiratori M, Murakami S, Chiba H, Kon H, Kuroki Y and Abe S: Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. Eur Respir J 17: 481-487, 2001.
115. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K and Yamakido M: Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 18: 203-216, 1988.
116. Stahel RA, Gilks WR, Lehmann HP and Schenker T: Third interaction workshop on lung tumor and differentiation antigens: overview of the results of the central data analysis. Int J Cancer 59(Suppl. 8): S6-26, 1994.
117. Yokoyama A, Kohno N, Kondo K, Ueda S, Hirasawa Y, Watanabe K, Takada Y and Hiwada K: Comparative evaluation of sialylated carbohydrate antigens, KL-6, CA 19-9, and SLX as serum markers for interstitial pneumonia. Respirology 3: 199-202, 1998.
118. Kobayashi J and Kitamura S: KL-6: a serum marker for interstitial pneumonia. Chest 108: 1-5, 1995.
119. Kohno N, Kyoizumi S, Awaya Y, Fukurama H, Yamakido M and Akiyama M: New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 96: 68-73, 1989.
120. Kara R, Itami J, Komiyama T, Katoh D and Kondo T: Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 125: 340-344, 2004.
121. Goto K, Kodama T, Sekine I, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Ikeda H, Ando M and Nishiwaki Y: Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer 34: 141-148, 2001.
122. Matsuno Y, Satoh H, Ishikawa H, Kodama T, Ohtsuka M and Sekizawa K: Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy. Medical Oncology 23: 75-81, 2006.
123. Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda Y, Bandoh S, Yamaji Y, Ohtsuki Y, Dobashi N, Ishida T and Takahara J: The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA 21-1) in human lung cancer cell Unes. Int J Cancer 91: 468-473, 2001.
124. Prasad S, Soldatenkov VA, Srinivasarao G and Dritschilo A: Identification of keratins 18, 19 and heat-shock protein 90β as candidate substrates of proteolysis during ionizing radiation-induced apoptosis of estrogen-receptor negative breast tumor cells. Int J Oncol 13: 757-764, 1998.
125. Fujita J, Ohtsuki Y, Bandoh S, Takashima H, Ueda Y, Wu F, Tojo Y, Kubo A and Ishida T: Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage. Respir Med 98: 294-300, 2004.
126. Hauer-Jensen M, Kong FM, Fink LM and Anscher MS: Circulating thrombomodulin during radiation therapy of lung cancer. Radiat Oncol Investig 7: 238-242, 1999.
127. Bentzen SM, Dorr W, Anscher MS, Denham JW, Hauer-Jensen M, Marks LB and Williams J: Normal tissue effects: reporting and analysis. Sem Radiat Oncol 13: 189-202, 2003.